New York, May 21, 2026, 05:05 EDT
- Rocket Lab set up a program to sell up to $3 billion of common stock and related forward sales.
- Shares fell in extended trading after the filing, giving back part of a sharp 2026 rally.
- SpaceX’s public IPO filing added a new yardstick for investors valuing launch and satellite companies.
Rocket Lab Corp’s stock was under pressure before Thursday’s regular U.S. open after the space company filed plans to sell up to $3 billion of common stock, a move that raised dilution worries just as SpaceX put fresh scale pressure on the sector with its long-awaited IPO paperwork. Rocket Lab shares were quoted around $126.75 in early trading, after the stock closed Wednesday at $134.28.
The timing matters. Rocket Lab had become one of the most visible public bets on launch services, satellites and defense-linked space hardware, and Benzinga said the shares were up about 92% year-to-date before the late-Wednesday filing.
Nasdaq’s regular session had not opened at the dateline. The exchange says its premarket session runs from 4:00 a.m. to 9:30 a.m. Eastern time, before the core market opens at 9:30 a.m.; its 2026 holiday calendar lists the next U.S. closure as Memorial Day on Monday, May 25.
Rocket Lab said in an 8-K that it entered an equity distribution agreement with a group of banks and brokerages, allowing it to sell shares from time to time through agents or as principal. An at-the-market offering, in plain terms, lets a company sell stock gradually at prevailing market prices instead of doing one large priced deal all at once.
The company said proceeds would fund future growth, potential acquisitions, and general corporate and working-capital needs. The same filing also lays out forward-sale structures, where banks may borrow and sell shares as a hedge before Rocket Lab later receives proceeds or settles the transaction.
This is not a weak operating story, at least on the latest numbers. Rocket Lab reported first-quarter revenue of $200.3 million, up 63.5% from a year earlier, a record $2.2 billion backlog, and more than $2 billion in liquidity; it guided second-quarter revenue to $225 million to $240 million.
Still, fresh stock can come with a cost. Dilution means existing holders own a smaller slice of the company, and Rocket Lab warned in the prospectus that sales under the program, or future sales, may depress the share price. It also said additional issuances could dilute earnings per share if the proceeds do not generate enough revenue to offset the effect.
The competitive backdrop changed overnight. SpaceX filed publicly on Wednesday for an initial public offering — the first sale of shares to public investors — and said it had picked Nasdaq for the listing, Reuters reported.
SpaceX’s numbers are much larger. Investor’s Business Daily, citing the prospectus, said SpaceX posted $4.694 billion of revenue in the first quarter and $18.674 billion in 2025 revenue, with the Starlink connectivity business driving much of the total.
That puts Rocket Lab in a tighter comparison set. MarketWatch reported Rocket Lab fell more than 6% in after-hours trading after SpaceX’s filing, while other space names including Voyager Technologies and Firefly Aerospace also weakened, though less sharply.
Analysts and traders split on what SpaceX means for the market. Dan Ives, head of technology research at Wedbush Securities, said the IPO places SpaceX at the center of two large growth opportunities, while Dennis Dick of Triple D Trading was more cautious, calling a potential $2 trillion valuation “a little scary.” Reuters
For Rocket Lab, the risk paragraph is simple. If investors see the $3 billion program as smart funding after a rally, the company gets more room for acquisitions, Neutron development and defense work. If they see it as too much stock too soon, the shares could stay heavy even with a growing backlog.
